中华皮肤科杂志 ›› 2024, e20240014.doi: 10.35541/cjd.20240014
郑瑀心 郑敏
收稿日期:2024-01-12
修回日期:2024-05-30
发布日期:2024-08-12
通讯作者:
郑敏
E-mail:minz@zju.edu.cn
基金资助:Zheng Yuxin, Zheng Min
Received:2024-01-12
Revised:2024-05-30
Published:2024-08-12
Contact:
Zheng Min
E-mail:minz@zju.edu.cn
Supported by:摘要： 【摘要】 近年来，银屑病的管理方式不断发展，但仍存在许多“惑”与“解”的问题，本文主要围绕银屑病的管理目标、早期干预的获益、以患者为中心的治疗方案、生物制剂的选择与转换、复发管理策略、未满足的需求展开综述，旨在为患者和医护人员提供参考。
郑瑀心 郑敏. 从困惑到明晰：银屑病慢病管理的探索与实践[J]. 中华皮肤科杂志, 2024,e20240014. doi:10.35541/cjd.20240014
Zheng Yuxin, Zheng Min. From confusion to clarity: exploration and practice in the chronic disease management of psoriasis[J]. Chinese Journal of Dermatology,2024,e20240014. doi:10.35541/cjd.20240014
| ［1］ | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839. |
| ［2］ | Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL⁃23 and IL⁃17 pathway in psoriasis［J］. Lancet, 2021,397（10275）:754⁃766. doi: 10.1016/S0140⁃6736（21）00184⁃7. |
| ［3］ | Campanati A, Marani A, Martina E, et al. Psoriasis as an immune⁃mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches［J］. Biomedicines, 2021,9（11）:1511. doi: 10.3390/biomedicines9111511. |
| ［4］ | Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage?［J］. Exp Dermatol, 2014,23（10）:705⁃709. doi: 10.1111/exd. 12437. |
| ［5］ | 中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. doi: 10.35541/cjd.20220652. |
| ［6］ | Wang K, Zhao Y, Cao X. Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030［J］. Arch Dermatol Res, 2024,316（4）:114. doi: 10.1007/s00403⁃024⁃02846⁃z. |
| ［7］ | Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council［J］. J Am Acad Dermatol, 2020,82（1）:117⁃122. doi: 10.1016/j.jaad.2019.08.026. |
| ［8］ | Krueger JG, Wharton KA Jr, Schlitt T, et al. IL⁃17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis［J］. J Allergy Clin Immunol, 2019,144（3）:750⁃763. doi: 10.1016/j.jaci.2019.04.029. |
| ［9］ | Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance （'clinical super response'）: week 28 results from the ongoing phaseⅢb randomized, double⁃blind, parallel⁃group, GUIDE study［J］. J Eur Acad Dermatol Venereol, 2023,37（10）:2016⁃2027. doi: 10.1111/jdv.19236. |
| ［10］ | Huang YW, Tsai TF. Remission duration and long⁃term outcomes in patients with moderate⁃to⁃severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15⁃year single⁃center experience［J］. Dermatol Ther （Heidelb）, 2019,9（3）:553⁃569. doi: 10.1007/s13555⁃019⁃0310⁃5. |
| ［11］ | Kampylafka E, Simon D, d'Oliveira I, et al. Disease interception with interleukin⁃17 inhibition in high⁃risk psoriasis patients with subclinical joint inflammation⁃data from the prospective IVEPSA study［J］. Arthritis Res Ther, 2019,21（1）:178. doi: 10.1186/s13075⁃019⁃1957⁃0. |
| ［12］ | von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. doi: 10.1016/j.jid.2018. 10.042. |
| ［13］ | Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2024,38（5）:e424⁃e427. doi: 10.1111/jdv.19652. |
| ［14］ | Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new⁃onset psoriasis: aiming to understand the potential for disease modification ⁃ rationale and design of the randomized, multicenter STEPIn study［J］. J Eur Acad Dermatol Venereol, 2018,32（11）:1930⁃1939. doi: 10.1111/jdv.14979. |
| ［15］ | Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow⁃band ultraviolet B phototherapy in new⁃onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study［J］. J Eur Acad Dermatol Venereol, 2023,37（5）:1004⁃1016. doi: 10.1111/jdv.18846. |
| ［16］ | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd.20210643. |
| ［17］ | Balakirski G, Gerdes S, Beissert S, et al. Therapy of psoriasis during pregnancy and breast⁃feeding［J］. J Dtsch Dermatol Ges, 2022,20（5）:653⁃683. doi: 10.1111/ddg.14789. |
| ［18］ | Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6. |
| ［19］ | Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8. |
| ［20］ | Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.0000000 000001163. |
| ［21］ | Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phaseⅢ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041. |
| ［22］ | Schett G, McInnes IB, Neurath MF. Reframing immune⁃mediated inflammatory diseases through signature cytokine hubs［J］. N Engl J Med, 2021,385（7）:628⁃639. doi: 10.1056/NEJMra1909094. |
| ［23］ | Blair HA. Secukinumab: a review in psoriatic arthritis［J］. Drugs, 2021,81（4）:483⁃494. doi: 10.1007/s40265⁃021⁃01476⁃3. |
| ［24］ | Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis （GRAPPA）: updated treatment recommendations for psoriatic arthritis 2021［J］. Nat Rev Rheumatol, 2022,18（8）:465⁃479. doi: 10.1038/s41584⁃022⁃00798⁃0. |
| ［25］ | Singla S, Putman M, Liew J, et al. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study［J］. Lancet Rheumatol, 2023,5（4）:e200⁃e207. doi: 10.1016/S2665⁃9913（23）00034⁃6. |
| ［26］ | Morita A, Tsai TF, Yee E, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double⁃blind, placebo⁃controlled Effisayil™ 1 study［J］. J Dermatol, 2023,50（2）:183⁃194. doi: 10.1111/1346⁃8138.16609. |
| ［27］ | Rosi E, Fastame MT, Di Cesare A, et al. Targeting IL⁃17A for the treatment of pustular psoriasis: a comprehensive review［J］. Expert Opin Biol Ther, 2022,22（12）:1475⁃1487. doi: 10.1080/14712598.2022.2116978. |
| ［28］ | Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a new era?［J］. Clin Cosmet Investig Dermatol, 2023,16:1677⁃1690. doi: 10.2147/CCID.S407812. |
| ［29］ | 中国医师协会皮肤科医师分会，中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）［J］．中华皮肤科杂志，2024,57（5）:409⁃417. doi: 10.35541/cjd. 20230570. |
| ［30］ | Potestio L, Camela E, Cacciapuoti S, et al. Biologics for the management of erythrodermic psoriasis: an updated review［J］. Clin Cosmet Investig Dermatol, 2023,16:2045⁃2059. doi: 10. 2147/CCID.S407813. |
| ［31］ | 周颖, 沙扬, 于浈, 等. 红皮病型银屑病治疗的研究进展［J］. 中国医学前沿杂志（电子版）, 2023,15（11）:21⁃28. doi: 10. 12037/YXQY.2023.11⁃04. |
| ［32］ | Ruiz⁃Villaverde R, Rodriguez⁃Fernandez⁃Freire L, Armario⁃Hita JC, et al. Guselkumab as a switching strategy after anti⁃TNFα, anti⁃IL17, or anti⁃IL12/23 therapies in moderate⁃to⁃severe psoriasis［J］. Dermatol Ther, 2022,35（10）:e15760. doi: 10.1111/dth.15760. |
| ［33］ | Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti⁃IL17: a 52⁃week real⁃life study［J］. J Dermatolog Treat, 2022,33（5）:2560⁃2564. doi: 10.1080/09546634.2022.2036674. |
| ［34］ | Liu S, He M, Jiang J, et al. Triggers for the onset and recurrence of psoriasis: a review and update［J］. Cell Commun Signal, 2024,22（1）:108. doi: 10.1186/s12964⁃023⁃01381⁃0. |
| ［35］ | Wang W, Qiu Y, Zhao F, et al. Poor medication adherence in patients with psoriasis and a successful intervention［J］. J Dermatolog Treat, 2019,30（6）:525⁃528. doi: 10.1080/09546634. 2018.1476652. |
| ［36］ | Blauvelt A, Reich K, Warren RB, et al. Secukinumab re⁃initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis［J］. Br J Dermatol, 2017,177（3）:879⁃881. doi: 10.1111/bjd.15656. |
| ［37］ | Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL⁃23⁃regulated IL⁃17 and IL⁃22 in psoriasis: VOYAGE 2 study［J］. J Invest Dermatol, 2019,139（12）:2437⁃2446.e1. doi: 10.1016/j.jid.2019.05.016. |
| ［38］ | McInnes IB, Gravallese EM. Immune⁃mediated inflammatory disease therapeutics: past, present and future［J］. Nat Rev Immunol, 2021,21（10）:680⁃686. doi: 10.1038/s41577⁃021⁃00603⁃1. |
| ［39］ | Tang X, Li Q, Zhou Y, et al. Predictive factors of atopic⁃like dermatitis induced by IL⁃17A inhibitors in patients with psoriasis: a 2⁃year follow⁃up study［J］. J Eur Acad Dermatol Venereol, 2023,37（12）:2509⁃2516. doi: 10.1111/jdv.19394. |
| ［40］ | van der Schoot LS, van den Reek J. Data⁃driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine［J］. Br J Dermatol, 2021,185（4）:698⁃699. doi: 10. 1111/bjd.20625. |
| ［41］ | Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment⁃as⁃needed versus fixed⁃interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double⁃blind, noninferiority trial （SCULPTURE）［J］. J Am Acad Dermatol, 2015,73（1）:27⁃36.e1. doi: 10.1016/j.jaad.2015.04.011. |
| ［42］ | Blauvelt A, Ferris LK, Yamauchi PS, et al. Extension of ustekinumab maintenance dosing interval in moderate⁃to⁃severe psoriasis: results of a phaseⅢb, randomized, double⁃blinded, active⁃controlled, multicentre study （PSTELLAR）［J］. Br J Dermatol, 2017,177（6）:1552⁃1561. doi: 10.1111/bjd.15722. |
| ［43］ | Ye LR, Yan BX, Chen XY, et al. Extended dosing intervals of ixekizumab for psoriasis: a single⁃center, uncontrolled, prospective study［J］. J Am Acad Dermatol, 2022,86（6）:1348⁃1350. doi: 10.1016/j.jaad.2021.04.093. |
| ［44］ | Chen XB, Zheng YX, Ye LR, et al. Gradually increasing the dosing interval of secukinumab for moderate to severe plaque psoriasis: a single⁃center, uncontrolled, prospective study in 36 weeks［J］. Dermatol Ther, 2022,35（12）:e15911. doi: 10.1111/dth.15911. |
| ［45］ | Zheng YX, Zheng M. A multidisciplinary team for the diagnosis and management of psoriatic arthritis［J］. Chin Med J （Engl）, 2021,134（12）:1387⁃1389. doi: 10.1097/CM9.0000000000001588. |
| ［46］ | Liu Z, Wang X, Ma Y, et al. Artificial intelligence in psoriasis: where we are and where we are going［J］. Exp Dermatol, 2023,32（11）:1884⁃1899. doi: 10.1111/exd.14938. |
| [1] | 陈嘉琪 张禁 唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 84-88. |
| [2] | 金兰 邱云 王唯嘉 康晓静 丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52. |
| [3] | 王博 郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75. |
| [4] | 乔嘉熙 夏萍 陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829. |
| [5] | 窦进法 王建波 张帅 李建国 刘鸿伟 张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 57(8): 739-742. |
| [6] | 林子沅 庞天怡 武静文 靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769. |
| [7] | 宋雨晴 杨楠 刘琳琳 冯子仪 韩世新 周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746. |
| [8] | 隋长霖 常晓 赵琪 朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574. |
| [9] | 陆佳维 鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482. |
| [10] | 张元文 孙从乾 潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475. |
| [11] | 郭澜 晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478. |
| [12] | 胡梦瑶 李敏 陈思涵 魏雪翠 陈宇杰 徐松 陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444. |
| [13] | 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417. |
| [14] | 严汝帆 廖洁月 郭子瑜 姚南 周文玉 罗帅寒天 张桂英 赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378. |
| [15] | 岳淑珍 树叶 罗鸯鸯 李珂瑶 张圆圆 汤建萍 韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358. |
|
